{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-005743","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.682973+00:00","generated_at":"2026-06-06T20:10:43.044326+00:00","sec_items":["9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Liquidia: United Therapeutics dismisses '793 Patent claims in PH-ILD litigation; '327 Patent remains","bullets":["On Jan 22, 2024, United Therapeutics stipulated to dismiss all claims related to the '793 Patent in the New Hatch-Waxman Litigation.","Only claims related to the '327 Patent remain; Liquidia asserts the '327 Patent does not entitle a 30-month regulatory stay.","The dismissal does not affect the injunction issued in the Original Hatch-Waxman Litigation (filed June 2020).","Liquidia's motion to set aside the original injunction is fully briefed; awaiting the District Court's decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-005743","json":"https://secwatch.observer/filing/0001104659-24-005743.json","markdown":"https://secwatch.observer/filing/0001104659-24-005743.md","text":"https://secwatch.observer/filing/0001104659-24-005743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924005743/0001104659-24-005743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924005743/tm243890d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:10:43.044326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}